10-K: Protagonist Therapeutics Advances Key Programs, Reports 2025 Net Loss

Protagonist Therapeutics submitted NDAs for Icotyde and rusfertide in 2025, expanded its pipeline, and ended the year with $646 million in cash despite a net loss.

Summary

• Protagonist Therapeutics, an integrated discovery and development company, focuses on inflammation & immunology, hematology, and metabolic diseases.
• Janssen Biotech, Inc. (JNJ) submitted New Drug Applications (NDAs) for Icotyde (icotrokinra) to the U.S. FDA in July 2025 and the European Medicines Agency (EMA) in September 2025 for moderate-to-severe plaque psoriasis, with a U.S. launch expected in 2026.
• Protagonist and Takeda Pharmaceuticals, Inc. (Takeda) submitted an NDA for rusfertide in December 2025 for polycythemia vera (PV), with a U.S. launch expected in the second half of 2026. Rusfertide received Orphan Drug status, Fast Track designation, and Breakthrough Therapy designation (BTD) in 2025.
• The company initiated a Phase 1 trial for PN-881, an oral IL-17 antagonist, in October 2025, with Phase 2 in psoriasis expected by the end of 2026.
• Two new obesity candidates, PN-477 (triple agonist) and PN-458 (dual agonist), were nominated in June and December 2025, respectively, with Phase 1 studies for PN-477 anticipated in mid-2026 and the second half of 2026.
• An oral hepcidin mimetic, PN-8047, was nominated in December 2025 for PV, with IND-enabling studies ongoing.
• Cash, cash equivalents, and marketable securities increased to $646.0 million as of December 31, 2025, from $559.2 million in 2024.
• The company reported a net loss of $130.1 million for the year ended December 31, 2025, compared to a net income of $275.2 million in 2024.
• License and collaboration revenue decreased significantly to $46.0 million in 2025 from $434.4 million in 2024, primarily due to the timing of milestone payments.
• Research and development expenses increased by 15% to $159.3 million in 2025, driven by new preclinical and Phase 1 programs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While significant pipeline advancements and regulatory submissions for key assets are positive, the substantial net loss and sharp decline in collaboration revenue in 2025, albeit due to timing of milestones, indicate ongoing financial challenges typical of a clinical-stage biopharmaceutical company.

Positives

• Icotyde and rusfertide NDAs submitted to FDA and EMA in 2025, indicating significant progress towards commercialization.
• Rusfertide received Orphan Drug, Fast Track, and Breakthrough Therapy designations, which can expedite development and provide market exclusivity.
• Strong cash position of $646.0 million at year-end 2025, providing funding for at least the next 12 months.
• Expansion of the pipeline with new obesity candidates (PN-477, PN-458) and an oral hepcidin mimetic (PN-8047), diversifying future growth potential.
• JNJ projects Icotyde peak year sales at greater than $5.0 billion, and rusfertide has a peak revenue potential of $1.0 to $2.0 billion.
• Successful completion of the Phase 3 VERIFY trial for rusfertide, leading to a $25.0 million milestone payment from Takeda.
• Potential for significant future milestone and royalty payments from JNJ (up to $630.0 million) and Takeda (up to $975.0 million if opt-out exercised, plus up to $400.0 million for opt-out payments).
• Effective internal controls over financial reporting and disclosure controls and procedures as of December 31, 2025.

Negatives

• Reported a net loss of $130.1 million in 2025, a significant decline from the $275.2 million net income in 2024.
• License and collaboration revenue decreased by 89% from $434.4 million in 2024 to $46.0 million in 2025, primarily due to the timing of large milestone payments in the prior year.
• The company has incurred a cumulative net loss of $470.7 million since inception and expects to incur significant losses in the future.
• No approved products and no historical commercial revenue, making future prospects and financial results difficult to assess.
• Dependence on third-party collaborators (JNJ, Takeda) for development and commercialization, with risks of termination or disagreements.
• Rusfertide clinical studies were subject to a three-week clinical hold by the FDA in September 2021 due to a non-clinical finding of benign and malignant subcutaneous skin tumors in a mouse model.
• The company may require additional funding in the future, which could lead to dilution for existing stockholders or relinquishing rights to product candidates.

Risks

• Heavy dependence on the success of product candidates in clinical development; failure at any stage could adversely affect the business.
• No approved products and no historical commercial revenue, making future prospects and financial results difficult to assess.
• Clinical development is a lengthy, expensive process with an uncertain outcome, and results of earlier studies may not predict future trial results.
• Inability to discover and develop new product candidates would adversely affect the business.
• Product candidates may cause undesirable side effects or have other properties adversely impacting safety, delaying or preventing regulatory approval, restricting labeling, or limiting commercial opportunity (e.g., rusfertide non-clinical finding of skin tumors in mice).
• Incurred a cumulative net loss since inception and may incur significant losses in the future.
• May require additional funding, which may not be available on acceptable terms or at all, potentially leading to dilution or relinquishing rights.
• Reliance on JNJ and Takeda for development and commercialization of Icotyde and rusfertide, respectively, with risks of termination or unsuccessful efforts.
• Reliance on third parties (CROs, CMOs) to conduct pre-clinical studies, clinical trials, and manufacturing, posing risks if they fail to meet obligations or deadlines.
• Potential business combinations or other strategic transactions may disrupt business or divert management's attention.
• Regulatory approval processes are lengthy and time-consuming, and approval is not guaranteed.
• Disruptions at the FDA and other government agencies (e.g., government shutdowns, workforce reductions) could negatively affect regulatory review.
• May fail to obtain additional orphan drug designations or maintain associated benefits, including market exclusivity.
• Currently has no marketing and sales organization and would need to build or partner to commercialize approved products.
• Recently enacted and future legislation (e.g., ACA, IRA) may increase difficulty and cost of obtaining marketing approval and commercializing products, and affect prices.
• The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.
• Conducts a substantial portion of clinical trials outside the United States, exposing the company to risks of doing business abroad.
• Commercial success depends on market acceptance by physicians, patients, and third-party payors.
• Market opportunities for approved product candidates may be smaller than expected.
• Competition from generic versions of approved product candidates could adversely affect sales.
• Faces significant competition from other biotechnology and pharmaceutical companies, many with greater resources.
• Outbreaks of disease, epidemics, and pandemics could adversely impact business, including clinical trials.
• Unstable market and macroeconomic conditions (inflation, tariffs, geopolitical conflicts) may have serious adverse consequences.
• Cash held at financial institutions often exceeds federally insured limits, posing a risk in case of bank failures.
• Failure to comply with state and federal healthcare regulatory laws could lead to substantial penalties.
• Future success depends on the ability to retain executive officers and attract, retain, and motivate qualified personnel.
• May experience difficulties in managing the growth of the organization.
• Significant disruptions of information technology systems or cybersecurity incidents could adversely affect the business, with AI increasing sophistication of attacks.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Misconduct by employees, independent contractors, principal investigators, consultants, and vendors could have a material adverse effect.
• Product liability lawsuits could result in substantial liabilities.
• Headquarters located near known earthquake fault zones.
• Inability to obtain or protect intellectual property rights could hinder competition.
• Involvement in lawsuits to protect or enforce intellectual property could be expensive and time-consuming.
• Patents covering product candidates could be found invalid or unenforceable.
• Third-party claims of intellectual property infringement may prevent or delay drug discovery and development.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Claims challenging the inventorship or ownership of intellectual property, including U.S. government rights under the Bayh-Dole Act.
• Reliance on third parties requires sharing trade secrets, increasing risk of discovery or misappropriation.
• Intellectual property rights do not necessarily address all potential threats to the business.
• Stock price has been and will likely continue to be volatile and may decline regardless of operating performance.
• Required to develop and maintain proper and effective internal controls over financial reporting, and any failure could adversely affect investor confidence.
• Shareholder activism could cause material disruption.
• Delaware exclusive forum provision could limit stockholders' ability to obtain a favorable judicial forum.
• Provisions of charter documents and Delaware law may have anti-takeover effects.
• Ability to use net operating loss carryforwards and tax credit carryforwards may be subject to limitations (Section 382/383).
• Inaccurate estimates or assumptions in financial statements could lead to variations in actual results.
• Could be subject to additional tax liabilities due to changes in tax legislation (e.g., One Big Beautiful Bill Act).

Future Outlook

Protagonist Therapeutics anticipates the U.S. launch of Icotyde in 2026 and rusfertide in the second half of 2026, both subject to regulatory approval. The company expects to complete the Phase 1 study for PN-881 by mid-2026 and initiate a Phase 2 study in psoriasis by the end of 2026. Phase 1 clinical studies for PN-477sc and PN-477o are anticipated by mid-2026 and the second half of 2026, respectively. The company expects to exercise its Full Opt-out Right under the Takeda Collaboration Agreement in the second quarter of 2026, which would lead to significant additional payments and enhanced royalties.

Management Comments

• Our aim is to develop medicines for biologically and commercially validated targets which demonstrate a strong differentiation compared to existing therapies.
• We believe that the use of contract manufacturing organizations (CMOs) eliminates the need for us to directly invest in manufacturing facilities, equipment and additional staff.
• We believe that our focus and expertise will help us develop products based on our proprietary intellectual property.
• We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next 12 months.
• We believe an IL-17 antagonist peptide like PN-881, with best-in-class potential as an oral targeted therapy, may offer an attractive therapeutic option for patients with broad opportunity for multiple indications in addition to psoriasis.
• We believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries may cause us to price our product candidates on less favorable terms than we currently anticipate.

Industry Context

StockSavvy.ai notes that Protagonist Therapeutics operates in highly competitive biotechnology and pharmaceutical industries, characterized by rapid technological change and significant market opportunities in chronic inflammatory, hematologic, and metabolic diseases. The company's focus on oral peptide therapies addresses a key unmet need for convenience and adherence in markets currently dominated by injectable biologics, such as those for psoriasis (e.g., Stelara, Tremfya, Skyrizi) and obesity (e.g., Wegovy, Zepbound). The substantial growth projected for anti-obesity medications (>$120 billion by 2034) and psoriasis therapies (>$39 billion by 2030) underscores the strategic importance of Protagonist's pipeline expansion. However, the industry faces increasing pressure from cost-containment measures and generic competition, which could impact pricing and reimbursement for new therapies.

Comparison to Industry Standards

• Icotyde is a first-in-class oral IL-23R antagonist, aiming to differentiate from existing injectable IL-23 inhibitors like JNJ's Stelara ($6.1 billion global sales in 2025) and Tremfya ($5.2 billion in 2025), and AbbVie's Skyrizi.
• PN-881, an oral IL-17 antagonist, seeks to compete with established injectable IL-17 inhibitors such as Novartis' Cosentyx and Eli Lilly's Taltz, and newer entrants like UCB's Bimzelx, by offering oral convenience.
• Rusfertide, a first-in-class injectable hepcidin mimetic for PV, aims to address unmet needs where current treatments like Incyte's Jakafi (ruxolitinib) and PharmaEssentia's Besremi (ropeginterferon alfa-2b) have limitations in hematocrit control and side effect profiles.
• PN-477 (triple GLP-1, GIP, GCG agonist) and PN-458 (dual GLP-1, GIP agonist) are positioned against market leaders like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide), and emerging triple agonists like Eli Lilly's retatrutide, by offering oral formulations and potentially improved body composition outcomes. PN-458 demonstrates higher in vitro potency than tirzepatide for target receptors.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.
• In January 2020, the company initiated arbitration proceedings against Zealand Pharma A/S, which was resolved in August 2021 with an Arbitration Resolution Agreement obligating the company to make certain milestone and royalty payments for rusfertide.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises; stock price volatility; potential for significant returns if product candidates are successfully commercialized; impact from changes in corporate governance (e.g., increased authorized shares, anti-takeover provisions).
• Employees: Continued investment in human capital, competitive compensation, benefits (100% U.S. healthcare premiums), professional growth opportunities, and a safe working environment.
• Customers (Patients): Development of first-in-class oral therapies for chronic inflammatory, hematologic, and metabolic diseases aims to address unmet medical needs, improve convenience, and expand treatment options.
• Collaborators (JNJ, Takeda): Ongoing collaboration agreements with potential for significant milestone and royalty payments, but also risks of disagreements or termination.
• Creditors: Strong cash position of $646.0 million provides financial stability.

Next Steps

• JNJ expects to launch Icotyde in the United States in 2026, subject to regulatory approval.
• Takeda expects to launch rusfertide in the second half of 2026, subject to regulatory approval.
• Complete the Phase 1 study of PN-881 in mid-2026.
• Initiate a Phase 2 study of PN-881 in psoriasis by the end of 2026.
• Initiate Phase 1 clinical studies for PN-477sc by mid-2026 and PN-477o in the second half of 2026.
• Continue IND-enabling studies for PN-458o, PN-458sc, and PN-8047.
• Exercise the Full Opt-out Right under the Takeda Collaboration Agreement in the second quarter of 2026.
• Apply for patent term extensions for patents covering product candidates where possible.
• Continue to expand the portfolio of patents and patent applications.

Key Dates

Recommendation

Protagonist Therapeutics has made significant progress with two NDAs submitted for Icotyde and rusfertide, and a robust pipeline in early-stage development for large markets like obesity. The strong cash position provides a runway for continued operations. However, the substantial net loss in 2025 and the inherent risks of clinical development, regulatory approval, and commercialization for a company with no approved products warrant a cautious approach. The stock price has shown significant volatility, and while future milestone and royalty payments are substantial, they are contingent on successful approvals and commercial launches. A 'hold' recommendation reflects the promising pipeline and financial stability balanced against the significant execution risks and current unprofitability.

Keywords

biotechnology, pharmaceuticals, drug development, clinical trials, SEC filing, 10-K, Protagonist Therapeutics, PTGX, Icotyde, rusfertide, polycythemia vera, psoriasis, IL-23R antagonist, hepcidin mimetic, IL-17 antagonist, obesity, GLP-1, GIP, GCG, pipeline, regulatory approval, FDA, EMA, Janssen, Takeda, Orphan Drug, Breakthrough Therapy, Fast Track, financial results, net loss, cash resources, milestone payments, royalties, intellectual property, corporate governance, risk management